Document:

<PAGE>

                                                                   EXHIBIT 10.15

                           CRITICAL THERAPEUTICS, INC.

                              CONSULTING AGREEMENT

         This Agreement dated as of January 31, 2001 is between Critical
Therapeutics, Inc., a Delaware corporation (the "Company"), and H. Shaw Warren,
Jr., M.D. (the "Consultant"), a member of the medical staff at The General
Hospital Corporation doing business as Massachusetts General Hospital (together
with any other non-profit institution with which the Consultant may be
affiliated in the future, the "Institution").

1. SERVICES

         1.1 Services. The Company hereby retains the Consultant to perform such
consulting and advisory services in the Field (as defined in Section 1.2) as the
Company may from time to time reasonably request (the "Services"). The
Consultant shall also serve as a member of the Company's Scientific Advisory
Board ("SAB") until his membership is terminated by him or by written notice
from the Company's Board of Directors.

         1.2 The Field. During the term of this Agreement the term "Field" shall
mean the discovery and development of therapeutic products for application in
critical care and inflammation and diagnostic products intended to be sold in
conjunction with such therapeutic products. Following termination of this
Agreement, for purposes of Section l.4(a), the term "Field" shall be limited to
those projects that were either (a) actually undertaken by the Company or (b)
described in a written proposal approved by the Company's Board of Directors or
(c) pursued to the extent that the Company developed or obtained proprietary
scientific or business information relating thereto, before termination of this
Agreement.

         1.3 Commitment. The Consultant agrees to make himself available to
render the Services from time to time as requested by the Company at such times
and locations as may be mutually agreed provided that the Consultant shall not
be required to devote time equivalent to more than 42 days per year to the
performance of the Services.

         1.4 Exclusivity.

                  (a) Subject to the following sentence and subsection 1.4(c),
the Consultant agrees that he will not, without the approval of the Company,
render advice or services in the Field (whether as a director, scientific
advisory board member, officer, employee, consultant or otherwise) to a
for-profit entity. It is understood that nothing herein shall be construed to
restrict or limit the duties the Consultant is performing or may perform in the
course of, or incidental to, his appointment at the Institution, including but
not limited to research sponsored by a third party commercial entity, nor shall
anything herein be construed to restrict or limit the Consultant's right to
serve as an advisor to any hospital, or to any governmental or not-for-profit
organization. The Consultant's obligations under this subsection l.4(a) shall be
applicable during the term of this Agreement and for the one (1) year period
following termination of this Agreement.

<PAGE>

                  (b) Notwithstanding the foregoing, in the event that, during
the term of this Agreement, the Consultant performs research which is sponsored
by a third party commercial entity and in the Field, the Consultant shall
provide prompt written notice to the Company and the Company may, at its option,
terminate this Agreement as provided in Section 7.4.

                  (c) In the event that, at any time during the term of this
Agreement and the period of one (1) year following termination hereof, the
Consultant is not principally employed by the Institution and if,
notwithstanding a reasonably diligent search of not less than ninety (90) days
(the "Search Period"), he is unable (i) to find Alternate Employment with a
non-profit employer or (ii) because of the restrictions of Section l.4(a), to
find Alternate Employment with a for-profit employer, then the Company may only
enforce Consultant's obligations under this Section 1.4 after the expiration of
the Search Period if it either:

                  (x) narrows the scope of the "Field" to the extent that
         Section 1.4(a) does not bar any Alternate Employment he does find or

                  (y) pays the Consultant compensation in an amount equal to the
         Consultant's annual rate of compensation last received from the
         Institution, commencing at the end of the Search Period and continuing
         on a bi-weekly basis until such time as the Consultant commences
         Alternate Employment; provided that if Consultant would be able to
         secure Alternate Employment but for the lack of suitable compensation,
         the Company may enforce Consultant's obligations under Section 1.4(a)
         by paying Consultant an amount equal to the difference between the
         compensation last paid by the Institution to the Consultant and the
         compensation payable by such employment.

                  As used herein, "Alternate Employment" means a position
commensurate with Consultant's principal skills and the stature of his current
employment and at a level of compensation not less than that last paid
Consultant by the Institution.

2. TERM

         Subject to Section 7, this Agreement will be for a term beginning as of
the date set forth in the first paragraph and ending four years thereafter.

3. COMPENSATION AND EXPENSES

         3.1 Compensation. As full compensation for the Services, the Company
shall pay the Consultant (i) $75,000 during the first year of this Agreement,
(ii) $77,250 during the second year of this Agreement, (iii) $79,567.50 during
the third year of this Agreement and (iv) $81.954.53 during the fourth year of
this Agreement. Such fees shall be payable in arrears on the earlier of the date
of closing of the Company's first institutional equity financing or October 31,
2001, and thereafter bi-weekly in arrears in accordance with the Company's
regular payroll practices.

         3.2 Expenses. The Consultant shall be entitled to reimbursement for
reasonable travel and other out-or-pocket expenses incurred by the Consultant in
the performance of the Services

                                       2
<PAGE>

following submission of written expense statements and other supporting
documentation in accordance with the policy and practice of the Company.

4. THIRD PARTY RESTRICTIONS AND POLICIES

         4.1 Absence of Restrictions. The Consultant represents that, except as
set forth on Exhibit A, he is presently under no contractual or other
restriction or obligation which is inconsistent with the Consultant's execution
of this Agreement or the performance of the Services, and during the term of
this Agreement, the Consultant will not enter into any agreement, either written
or oral, which conflicts with this Agreement. In the event of any conflict
between the Consultant's obligations under this Agreement and his obligations
under any such other restriction or obligation set forth on Exhibit A, such
other restriction or obligation shall take precedence.

         4.2 Compliance with Institutional Policies. The Company recognizes
that, as a member of the medical staff of the Institution, the Consultant is
responsible for ensuring that any consulting agreement the Consultant enters
into with a for-profit entity is not in conflict with the patent, ownership of
inventions, consulting or other policies of the Institution, and the Consultant
represents and warrants that the Consultant has determined that this Agreement
complies with all such Institution policies. If the Consultant is required by
the Institution to disclose to it any proposed agreements, the Consultant
represents that he has made such disclosure and obtained any necessary formal
approvals of this Agreement by the Institution.

5. OWNERSHIP OF INVENTIONS

         5.1 "Inventions" means all inventions, ideas, discoveries,
developments, methods, data, information, improvements and biological or
chemical materials, (whether or not reduced to practice and whether or not
protectible under state, federal, or foreign patent, copyright, trade secrecy or
similar laws) which are conceived, created or developed by the Consultant
(whether alone or with others) (i) in the course of providing Services or as a
direct result of Confidential Information acquired by Consultant and on the
premises or at the direct expense of the Company and (ii) are not generated in
the course of the Consultant's activities as an employee of the Institution and
are not owned by the Institution or assignable to the Institution.

         5.2 Ownership by Company. Subject to Section 5.4 below, all Inventions
are and shall remain the exclusive property of the Company, and the Company may
use or pursue them without restriction or additional compensation. The
Consultant shall promptly and fully disclose to the Company any and all
Inventions. The Consultant shall maintain complete written records of all
Inventions and of all work or investigations done or carried out by the
Consultant at all stages thereof, which records shall be the exclusive property
of the Company.

         5.3 Assignment of Inventions. Subject to Section 5.4 below, the
Consultant hereby assigns and agrees to assign to the Company all of the
Consultant's right, title and interest in and to any Inventions. The Consultant
agrees to cooperate fully in obtaining patent, copyright or other proprietary
protection for such Inventions, all in the name of the Company and at the
Company's cost and expense, and shall execute and deliver all requested
applications,

                                       3
<PAGE>

assignments and other documents, and take such other measures, as the Company
shall reasonably request in order to perfect and enforce the Company's rights in
the Inventions (including transfer of possession to the Company of all
Inventions embodied in tangible materials), and hereby appoints the Company its
attorney to execute and deliver any such documents on its behalf in the event
the Consultant fails or refuses to do so.

         5.4 Avoidance of Claims by Institution. The Consultant will not perform
any Services for the Company on the premises of the Institution or with its
facilities or funds or in any other manner which could result in claims by
Institution of rights in any Inventions without the express prior agreement of
Company and Institution. In furtherance of the foregoing, the Company shall have
no rights under this Agreement in or to any publication, invention, discovery,
improvement, or other intellectual property whatsoever, whether or not
publishable, patentable, or copyrightable, which is developed as a result of
research under the control of the Institution. The Company also acknowledges and
agrees that it will enjoy no priority or advantage as a result of the
Consultant's consultancy created by this Agreement in gaining access, whether by
license or otherwise, to any proprietary information or intellectual property
that arises from any research undertaken by the Consultant in his capacity as an
employee of the Institution. Notwithstanding the foregoing, it is understood
that Consultant shall have the right to disclose, and shall disclose, to the
Institution's office of Corporate Sponsored Research and Licensing, in
confidence, all Inventions which relate to Consultant's research at the
Institution in order that the Institution may independently verify that such
Inventions are not subject to the policies of the Institution.

         5.5 Third Party Claims. Unless covered by an appropriate agreement
between any third party and the Company, the Consultant shall not engage in any
activities or use any facilities in the course of providing Services, which
could result in claims of ownership to any Inventions being made by such third
party.

6. CONFIDENTIAL INFORMATION AND MATERIALS

         6.1 "Materials" means all tangible biological or chemical materials
furnished to the Consultant by the Company in connection with performance of the
Services, as well as any other materials derived from such materials, including
any progeny derived from a cell line, monoclonal antibodies or recombinant
proteins produced from such materials, and substances routinely purified from
any source material included in such materials. It is understood that Materials
shall not include any tangible biological or chemical materials discovered, made
or prepared at the Institution by the Consultant or under the Consultant's
direction, and transferred to the Company by the Institution, nor shall it
include any derivatives of such materials and that the rights and obligations of
the Company and of the Consultant with respect to any such material shall be
governed by a duly executed agreement between the Institution and the
Consultant.

         6.2 "Confidential Information" means any information relating to the
scientific or business affairs of the Company that is treated by the Company as
confidential or proprietary. Confidential Information is contained in various
media, including records of research data and observations, records of clinical
trials, patent applications, computer programs, supply and

                                       4
<PAGE>

customer lists, internal financial data and other documents and records of the
Company, whether or not labeled or identified as "Confidential" or prepared by
the Consultant in the performance of the Services hereunder. Any similar
information obtained by or given to the Company about or belonging to its
suppliers, licensors, licensees, partners, affiliates, customers, potential
customers or others is referred to herein as "Third Party Confidential
Information" and is subject to the exclusions comparable to those set forth in
the next paragraph.

         Confidential Information does not include information which (a) was
known to the Consultant at the time it was disclosed, other than by previous
disclosure by the Company; (b) is at the time of disclosure or later becomes
publicly known under circumstances involving no breach of this Agreement; (c) is
made available to the Consultant by a third party who did not derive it from the
Company and who imposes no obligation of confidence on the Consultant; or (d) is
required to be disclosed by a governmental authority or by order of a court of
competent jurisdiction, provided that such disclosure is subject to all
available protection and reasonable advance notice is given to the Company.

         6.3 Consultant Acknowledgement. During the course of performing the
Services, Consultant may become aware of or have access to Confidential
Information and/or Materials. Consultant acknowledges the Company is and shall
at all times remain the sole owner of the Confidential Information and
Materials.

         6.4 Nondisclosure and Nonuse of Confidential Information and Materials.
The Consultant shall not directly or indirectly publish, disseminate or
otherwise disclose, deliver or make available to any third party any
Confidential Information, Materials Or Third Party Confidential Information,
other than in furtherance of the purposes of this Agreement, and only then with
the prior written consent of the Company; nor will the Consultant use such
Confidential Information, Materials or Third Party Confidential Information for
the Consultant's own benefit or for the benefit of any other third party.

         6.5 Publications. The Consultant agrees to submit to the Company a copy
of any proposed manuscript or other materials to be published or otherwise
publicly disclosed which contains information describing or deriving from those
activities within the Field with respect to which the Consultant has actually
performed Services for the Company prior to publication to enable the Company to
determine if patentable Inventions or Confidential Information of the Company
would be disclosed. The Company shall have a 45-day period in which to make such
determination. The Consultant shall cooperate with the Company in this respect
and shall delete from the manuscript or other disclosure any Confidential
Information if requested by the Company and shall assist the Company in filing
for patent protection for any patentable Inventions prior to publication or
other disclosure.

         6.6 Use and Return of the Confidential Information and Material. The
Consultant shall exercise all commercially reasonable precautions to protect the
integrity and confidentiality of the Confidential Information, Materials and
Third Party Confidential Information. The Consultant acknowledges that the use
of Materials is at the sole risk of the Consultant, and agrees to use the
Materials in accordance and compliance with any and all appropriate guidelines
or regulations established by any governmental authority. The Consultant will
not remove any

                                       5
<PAGE>

Confidential Information or copies thereof or physical samples of Materials from
the Company's premises except to the extent necessary to perform the Services.
Upon termination of this Agreement, and in any case upon the Company's request,
the Consultant shall return immediately to the Company all copies and other
tangible manifestations of Confidential Information and all Materials then in
the Consultant's possession or control. The Consultant shall return any Third
Party Confidential Information upon request of the third party or the Company.

7. TERMINATION

         7.1 Early Termination for Failure to Close Equity Financing. In the
event that the Company fails to consummate an equity financing raising at least
$10,000,000 on or prior to October 31, 2001, the Company may in its discretion
terminate this Agreement upon no less than thirty (30) days' prior written
notice given to the Consultant no later than November 30, 2001.

         7.2 Early Termination by the Consultant. The Consultant may terminate
this Agreement at any time without cause upon written notice to the Company.

         7.3 Early Termination by Either Party for Breach. In the event of any
material breach of this Agreement by either party that is not cured within ten
(10) days after written notice from the non-breaching party, the non-breaching
party may terminate this Agreement by giving written notice to the breaching
party; provided that (a) if such breach is incapable of being cured, this
Agreement shall terminate immediately upon such notice and (b) if such breach is
capable of being cured but cannot be cured within such 10-day period and the
breaching party has promptly commenced action to cure such breach and is
diligently prosecuting such cure, such breach shall not constitute grounds for
termination unless it is not cured within ninety (90) days after the
non-breaching party's notice of such breach.

         7.4 Early Termination for Conflicting Research. In the event that
Consultant gives notice of his intent to perform research which is sponsored by
a third party commercial entity and in the Field pursuant to Section 1.4 above,
the Company may, at its option, terminate this Agreement upon not less than ten
(10) days' prior written notice to the Consultant given within thirty (30) days
after the Consultant's notice.

         7.5 Early Termination due to Death or Disability. This Agreement shall
terminate upon the death of the Consultant or upon 30 days' written notice from
either party in the event of the Consultant's Disability. As used herein,
"Disability" means the Consultant's inability by reason of physical or mental
impairment to perform the services contemplated herein for ninety (90) or more
days within any six-month period.

         7.6 Effect of Termination. Termination of this Agreement shall not
affect any liabilities accrued hereunder through the date of termination. The
provisions of Sections 1.4(a), 5, 6, 7.6, and 8 shall survive termination;
provided that the Consultant's obligations under Sections 6.4 and 6.5 shall
survive for only five (5) years following termination. In the event this
Agreement is terminated after vesting and repurchase restrictions have been
imposed upon any shares of the Company's capital stock owned by the Consultant,
if and to the extent provided in a

                                       6
<PAGE>

separate Restricted Stock Agreement between Consultant and the Company,
termination of this Agreement shall result in termination of vesting of, and/or
the imposition of repurchase rights with respect to, certain shares held by the
Consultant.

8. MISCELLANEOUS

         8.1 Status. The Company and the Consultant agree that the Consultant
will be an independent contractor for all purposes, including but not limited to
payroll and tax purposes, and that the Consultant shall not, as a result of the
relationship established by this Agreement, in any way represent himself to be
an employee, partner, joint venturer or agent with or of the Company.

         8.2 Publicity. Subject to the policies of the Institution, Consultant
consents to the use by the Company of his name and likeness in written materials
or oral presentations to current or prospective customers, investors or others,
provided that such materials or presentations accurately and appropriately
describe the nature of Consultant's relationship with or contribution to the
Company, and further provided that Company shall have provided Consultant a
reasonable prior opportunity to review and comment thereon.

         8.3 Notice. All notices hereunder shall be in writing and shall be
given to the other party at the address or facsimile number set forth below, or
at such other address or facsimile number as either may specify in writing to
the other. All notices shall be effective when deposited in the United States
mail with proper postage for first class registered or certified mail, return
receipt requested, or when delivered personally or dispatched by facsimile,
addressed:

If to the Company:      CTI
                        PMB 461
                        One Kendall Square
                        Bldg 600
                        Cambridge, MA 02139
                        Facsimile:________________

If to the Consultant:   H. Shaw Warren, Jr.
                        40 Royal Avenue
                        Cambridge, MA 02138
                        Facsimile:________________

         8.4 Assignment. This Agreement, and the rights and obligations
hereunder, may not be assigned or transferred by either party without the prior
written consent of the other party; provided that the Company may assign this
Agreement to any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all of the business and/or
assets of the Company, but only if the Company obtains the agreement of such
successor to assume and agree to perform this Agreement in the same manner and
to the same extent that the Company would be required to perform it if no such
succession had taken place.

                                       7
<PAGE>

         8.5 Entire Agreement. This Agreement constitutes the entire agreement
of the parties, and supersedes all previous written or oral representations,
agreements and understandings between the Company and the Consultant, with
regard to the subject matter hereof. This Agreement may be amended or extended
only by a writing signed by both parties.(1)

         8.6 Applicable Law. This Agreement shall be governed by, and construed
in accordance with, the law of The Commonwealth of Massachusetts without regard
to any choice of law principle that would dictate the application of the law of
another jurisdiction.

         8.7 Consent to Jurisdiction. The parties to this Agreement hereby
irrevocably consent and submit to the exclusive jurisdiction of any Commonwealth
of Massachusetts or Federal court sitting in Boston in any action or proceeding
of any type whatsoever arising out of or relating to this Agreement.

         The parties hereby cause this Agreement to be signed as an instrument
under seal.

                                           CRITICAL THERAPEUTICS, INC.

                                           By:         /s/ H. Shaw Warren
                                              ----------------------------------
                                              Name:  H. Shaw Warren
                                              Title: Chair, Board

                                           CONSULTANT:

                                                       /s/ H. Shaw Warren
                                           -------------------------------------
                                           H. Shaw Warren, Jr., M.D.

__________________
(1)      N.B. Amendment is also restricted by Section 4.4(b) of the Company's
July __, 2001 Investor Rights Agreement.

                                       8
<PAGE>

                                    EXHIBIT A

                                  CONFIDENTIAL

                    PREEXISTING RESTRICTIONS AND OBLIGATIONS:

         Consultant is party to an Intellectual Property Agreement with The
Shriners Hospitals for Children.

         Consultant is party to an agreement to serve as a member of the
Scientific Advisory Board of Planet Biotechnology Inc.

         Consultant is party to a Scientific Advisory Board Member Agreement, a
Consulting Agreement, and a Confidential Disclosure Agreement with Verax
Biomedical Incorporated.

         Consultant is party to a Consulting and Scientific Advisory Board
Agreement with Surface Logix, Inc.

         Consultant is party to a Scientific Advisory Board Consulting Agreement
and a Confidential Disclosure Agreement with Advanced Medicine, Inc., both of
which will be renewed for an additional term of years in or about October 2001.

         Consultant is party to a Consulting Agreement with SAMTex, Inc.

<PAGE>

                           CRITICAL THERAPEUTICS, INC.

                                 AMENDMENT NO. 1

                                       TO

                              CONSULTING AGREEMENT

         This Amendment No. 1 dated February 6, 2003 (the "Amendment") to the
Consulting Agreement dated January 31, 2001 (the "Agreement") between Critical
Therapeutics, Inc., a Delaware corporation (the "Company"), and H. Shaw Warren,
Jr., M.D. (the "Consultant") is hereby entered into by the Company and the
Consultant. Except as set forth below, the Agreement shall remain in full force
and effect. Capitalized terms used herein and not otherwise defined shall have
the meanings assigned to them in the Agreement.

         For valuable consideration, receipt of which is acknowledged, the
parties hereto agree as follows:

         1. Acting in accordance with Section 8.5 of the Agreement, the
Agreement is hereby amended as follows:

                  a. Section 2 shall be deleted in its entirety and a new
Section 2 shall be inserted in lieu thereof which shall read as follows:

                           "Subject to Section 7, this Agreement will be for a
                  term beginning as of January 31, 2001 and ending on January
                  31, 2007."

                  b. Subsection 3.1 shall be deleted in its entirety and a new
Subsection 3.1 shall be inserted in lieu thereof which shall read as follows:

                           "Compensation. As full compensation for the Services,
                  the Company shall pay the Consultant (i) $75,000 during the
                  first year of this Agreement, (ii) $77,250 during the second
                  year of this Agreement, (iii) $79,567.50 during the third year
                  of this Agreement, (iv) $81,954.53 during the fourth year of
                  this Agreement, (v) $84,413.17 during the fifth year of this
                  Agreement and (vi) $86,945.57 during the sixth year of this
                  Agreement. Such fees shall be payable bi-weekly in arrears in
                  accordance with the Company's regular payroll practices."

         2. The Agreement, as supplemented and modified by this Amendment,
together with the other writings referred to in the Agreement or delivered
pursuant thereto which form a part thereof, contains the entire agreement among
the parties with respect to the subject matter thereof and amends, restates and
supersedes all prior and contemporaneous arrangements or understandings with
respect thereto.

         3. Upon the effectiveness of this Amendment, on and after the date
hereof, each reference in the Agreement to "this Agreement," "hereunder,"
"hereof," "herein" or words of like import, and each reference in the other
documents entered into in connection with the Agreement, shall mean and be a
reference to the Agreement as amended hereby. Except as specifically amended
above, the Agreement shall remain in full force and effect and is hereby
ratified and confirmed.

<PAGE>

         4. This Amendment shall be governed by, and construed in accordance
with, the law of The Commonwealth of Massachusetts without regard to any choice
of law principle that would dictate the application of the law of another
jurisdiction.

         5. This Amendment may be executed in counterparts, and each such
counterpart shall be deemed to be an original instrument, but all such
counterparts together shall constitute but one agreement.

         [The remainder of this page has intentionally been left blank.]

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Amendment No.
1 Consulting Agreement as of the day and year first above written.

                                           CRITICAL THERAPEUTICS, INC.

                                           By:   /s/ Paul Rubin
                                              ----------------------------------
                                           Name: Paul Rubin
                                           Title:

                                           CONSULTANT:

                                                 /s/ H. Shaw Warren, Jr., M.D.
                                           -------------------------------------
                                           H. Shaw Warren, Jr., M.D.<PAGE>
                                                                   Exhibit 10.16

                           CRITICAL THERAPEUTICS, INC.

                              CONSULTING AGREEMENT

      This Agreement dated as of January 31, 2001 is between Critical
Therapeutics, Inc., a Delaware corporation (the "Company"), and Mitchell Fink,
M.D. (the "Consultant"), a member of the medical staff at The University of
Pittsburgh Medical School (together with any other non-profit institution with
which the Consultant may be affiliated in the future, the "Institution").

1.    SERVICES

      1.1 Services. The Company hereby retains the Consultant to perform such
consulting and advisory services in the Field (as defined in Section 1.2) as the
Company may from time to time reasonably request (the "Services"). The
Consultant shall also serve as a member of the Company's Scientific Advisory
Board ("SAB") until his membership is terminated by him or by written notice
from the Company's Board of Directors.

      1.2 The Field. During the term of this Agreement, the term "Field" shall
mean the discovery and development of therapeutic products for application in
critical care and inflammation and diagnostic products intended to be sold in
conjunction with such therapeutic products. Following termination of this
Agreement, for purposes of Section 1.4(a), the term "Field" shall be limited to
those projects that were either (a) actually undertaken by the Company or (b)
described in a written proposal approved by the Company's Board of Directors or
(c) pursued to the extent that the Company developed or obtained proprietary
scientific or business information relating thereto, before termination of this
Agreement.

      1.3 Commitment The Consultant agrees to make himself available to render
the Services from time to time as requested by the Company at such times and
locations as may be mutually agreed, provided that the Consultant shall not be
required to devote time equivalent to more than 42 days per year to the
performance of the Services.

      1.4 Exclusivity.

            (a) Subject to the following sentence and subsection l.4(c), the
Consultant agrees that he will not, without the approval of the Company, render
advice or services in the Field (whether as a director, scientific advisory
board member, officer, employee, consultant or otherwise) to a for-profit
entity. It is understood that nothing herein shall be construed to restrict or
limit the duties the Consultant is performing or may perform in the course of,
or incidental to, his appointment at the Institution, including but not limited
to research sponsored by a third party commercial entity, nor shall anything
herein be construed to restrict or limit the Consultant's right to serve as an
advisor to any hospital, or to any governmental or not-for-profit organization.
The Consultant's obligations under this subsection 1.4(a) shall be applicable
during the term of this Agreement and for the one (1) year period following
termination of this Agreement.

<PAGE>

            (b) Notwithstanding the foregoing, in the event that, during the
term of this Agreement, the Consultant performs research which is sponsored by a
third party commercial entity and in the Field, the Consultant shall provide
prompt written notice to the Company and the Company may, at its option,
terminate this Agreement as provided in Section 7.4.

            (c) In the event that, at any time during the term of this Agreement
and the period of one (1) year following termination hereof, the Consultant is
not principally employed by the Institution and if, notwithstanding a reasonably
diligent search of not less than ninety (90) days (the "Search Period"), he is
unable (i) to find Alternate Employment with a non-profit employer or (ii)
because of the restrictions of Section 1.4(a), to find Alternate Employment with
a for-profit employer, then the Company may only enforce Consultant's
obligations under this Section 1.4 after the expiration of the Search Period if
it either.

                  (x) narrows the scope of the "Field" to the extent that
            Section 1.4(a) does not bar any Alternate Employment he does find or

                  (y) pays the Consultant compensation in an amount equal to the
            Consultant's annual rate of compensation last received from the
            Institution, commencing at the end of the Search Period and
            continuing on a bi-weekly basis until such time as the Consultant
            commences Alternate Employment; provided that if Consultant would be
            able to secure Alternate Employment but for the lack of suitable
            compensation, the Company may enforce Consultant's obligations under
            Section 1.4(a) by paying Consultant an amount equal to the
            difference between the compensation last paid by the Institution to
            the Consultant and the compensation payable by such employment.

            As used herein, "Alternate Employment" means a position commensurate
with Consultant's principal skills and the stature of his current employment and
at a level of compensation not less than that last paid Consultant by the
Institution.

2.    TERM

      Subject to Section 7, this Agreement will be for a term beginning as of
the date set forth in the first paragraph and ending four years thereafter.

3.    COMPENSATION AND EXPENSES

            3.1 Compensation. As full compensation for the Services, the Company
shall pay the Consultant (i) $75,000 during the first year of this Agreement,
(ii) $77,250 during the second year of this Agreement, (iii) $79,567.50 during
the third year of this Agreement and (iv) $81,954.53 during the fourth year of
this Agreement. Such fees shall be payable in arrears on the earlier of the date
of closing of the Company's first institutional equity financing or October 31,
2001, and thereafter bi-weekly in arrears in accordance with the Company's
regular payroll practices

            3.2 Expenses. The Consultant shall be entitled to reimbursement for
reasonable travel and other out-of-pocket expenses incurred by the Consultant in
the performance of the Services following submission of written expense
statements and other supporting documentation in accordance with the policy and
practice of the Company.

<PAGE>

4.    THIRD PARTY RESTRICTIONS AND POLICIES

      4.1 Absence of Restrictions. The Consultant represents that, except as set
forth on Exhibit A, he is presently under no contractual or other restriction or
obligation which is inconsistent with the Consultant's execution of this
Agreement or the performance of the Services, and during the term of this
Agreement, the Consultant will not enter into any agreement, either written or
oral, which conflicts with this Agreement. In the event of any conflict between
the Consultant's obligations under this Agreement and his obligations under any
such other restriction or obligation set forth on Exhibit A, such other
restriction or obligation shall take precedence.

      4.2 Compliance with Institutional Policies. The Company recognizes that,
as a member of the medical staff of the Institution, the Consultant is
responsible for ensuring that any consulting agreement the Consultant enters
into with a for-profit entity is not in conflict with the patent, ownership of
inventions, consulting or other policies of the Institution, and the Consultant
represents and warrants that the Consultant has determined that this Agreement
complies with all such Institution policies. If the Consultant is required by
the Institution to disclose to it any proposed agreements, the Consultant
represents that he has made such disclosure and obtained any necessary formal
approvals of this Agreement by the Institution.

5.    OWNERSHIP OF INVENTIONS

      5.1 "Inventions" means all inventions, ideas, discoveries, developments,
methods, data, information, improvements and biological or chemical materials,
(whether or not reduced to practice and whether or not protectible under state,
federal, or foreign patent, copyright, trade secrecy or similar laws) which are
conceived, created or developed by the Consultant (whether alone or with others)
(i) in the course of providing Services or as a direct result of Confidential
Information acquired by Consultant and on the premises or at the direct expense
of the Company and (ii) are not generated in the course of the Consultant's
activities as an employee of the Institution and are not owned by the
Institution or assignable to the Institution.

      5.2 Ownership by Company. Subject to Section 5.4 below, all Inventions are
and shall remain the exclusive property of the Company, and the Company may use
or pursue them without restriction or additional compensation. The Consultant
shall promptly and fully disclose to the Company any and all Inventions. The
Consultant shall maintain complete written records of all Inventions and of all
work or investigations done or carried out by the Consultant at all stages
thereof, which records shall be the exclusive property of the Company.

      5.3 Assignment of Inventions. Subject to Section 5.4 below, the Consultant
hereby assigns and agrees to assign to the Company all of the Consultant's
right, title and interest in and to any Inventions. The Consultant agrees to
cooperate fully in obtaining patent, copyright or other proprietary protection
for such Inventions, all in the name of the Company and at the Company's cost
and expense, and shall execute and deliver all requested applications,
assignments and other documents, and take such other measures, as the Company
shall reasonably request in order to perfect and enforce the Company's rights in
the Inventions (including transfer of possession to the Company of all
Inventions embodied in tangible materials), and hereby appoints the Company its
attorney to execute

<PAGE>

and deliver any such documents on its behalf in the event the Consultant fails
or refuses to do so.

      5.4 Avoidance of Claims by Institution. The Consultant will not perform
any Services for the Company on the premises of the Institution or with its
facilities or funds or in any other manner which could result in claims by
Institution of rights in any Inventions without the express prior agreement of
Company and Institution. In furtherance of the foregoing, the Company shall have
no rights under this Agreement in or to any publication, invention, discovery,
improvement, or other intellectual property whatsoever, whether or not
publishable, patentable, or copyrightable, which is developed as a result of
research under the control of the Institution. The Company also acknowledges and
agrees that it will enjoy no priority or advantage as a result of the
Consultant's consultancy created by this Agreement in gaining access, whether by
license or otherwise, to any proprietary information or intellectual property
that arises from any research undertaken by the Consultant in his capacity as an
employee of the Institution. Notwithstanding the foregoing, it is understood
that Consultant shall have the right to disclose, and shall disclose, to the
Institution's office of Corporate Sponsored Research and Licensing, in
confidence, all Inventions which relate to Consultant's research at the
Institution in order that the Institution may independently verify that such
Inventions are not subject to the policies of the Institution.

      5.5 Third Party Claims. Unless covered by an appropriate agreement between
any third party and the Company, the Consultant shall not engage in any
activities or use any facilities in the course of providing Services, which
could result in claims of ownership to any Inventions being made by such third
party.

6.    CONFIDENTIAL INFORMATION AND MATERIALS

      6.1 "Materials" means all tangible biological or chemical materials
furnished to the Consultant by the Company in connection with performance of the
Services, as well as any other materials derived from such materials, including
any progeny derived from a cell line, monoclonal antibodies or recombinant
proteins produced from such materials, and substances routinely purified from
any source material included in such materials. It is understood that Materials
shall not include any tangible biological or chemical materials discovered, made
or prepared at the Institution by the Consultant or under the Consultant's
direction, and transferred to the Company by the Institution, nor shall it
include any derivatives of such materials and that the rights and obligations of
the Company and of the Consultant with respect to any such material shall be
governed by a duly executed agreement between the Institution and the
Consultant.

      6.2 "Confidential Information" means any information relating to the
scientific or business affairs of the Company that is treated by the Company as
confidential or proprietary. Confidential Information is contained in various
media, including records of research data and observations, records of clinical
trials, patent applications, computer programs, supply and customer lists,
internal financial data and other documents and records of the Company, whether
or not labeled or identified as "Confidential" or prepared by the Consultant in
the performance of the Services hereunder. Any similar information obtained by
or given to the Company about or belonging to its suppliers; licensors,

<PAGE>

licensees, partners; affiliates, customers, potential customers or others is
referred to herein as "Third Party Confidential Information" and is subject to
the exclusions comparable to those set forth in the next paragraph.

      Confidential Information does not include information which (a) was known
to the Consultant at the time it was disclosed; other than by previous
disclosure by the Company; (b) is at the time of disclosure or later becomes
publicly known under circumstances involving no breach of this Agreement; (c) is
made available to the Consultant by a third Party who did not derive it from the
Company and who imposes no obligation of confidence on the Consultant; or (d) is
required to be disclosed by a governmental authority or by order of a court of
competent jurisdiction, provided that such disclosure is subject to all
available protection and reasonable advance notice is given to the Company.

      6.3 Consultant Acknowledgement. During the course of performing the
Services, Consultant may become aware of or have access to Confidential
Information and/or Materials. Consultant acknowledges the Company is and shall
at all times remain the sole owner of the Confidential Information and
Materials.

      6.4 Nondisclosure and Nonuse of Confidential Information and Materials.
The Consultant shall not directly or indirectly publish, disseminate or
otherwise disclose, deliver or make available to any third party any
Confidential Information, Materials or Third Party Confidential Information,
other than in furtherance of the purposes of this Agreement, and only then with
the prior written consent of the Company; nor will the Consultant use such
Confidential Information, Materials or Third Party Confidential Information for
the Consultant's own benefit or for the benefit of any other third party.

      6.5 Publications. The Consultant agrees to submit to the Company a copy of
any proposed manuscript or other materials to be published or otherwise publicly
disclosed which contains information describing or deriving from those
activities within the Field with respect to which the Consultant has actually
performed Services for the Company prior to publication to enable the Company to
determine if patentable Inventions or Confidential Information of the Company
would be disclosed. The Company shall have a 45-day period in which to make such
determination. The Consultant shall cooperate with the Company in this respect
and shall delete from the manuscript or other disclosure any Confidential
Information if requested by the Company and shall assist the Company in filing
for patent protection for any patentable Inventions prior to publication or
other disclosure.

      6.6 Use and Return of the Confidential Information and Material. The
Consultant shall exercise all commercially reasonable precautions to protect the
integrity and confidentiality of the Confidential Information, Materials and
Third Party Confidential Information. The Consultant acknowledges that the use
of Materials is at the sole risk of the Consultant, and agrees to use the
Materials in accordance and compliance with any and all appropriate guidelines
or regulations established by any governmental authority. The Consultant will
not remove any Confidential Information or copies thereof or physical samples of
Materials from the Company's premises except to the extent necessary to perform
the Services. Upon termination of this Agreement, and in any case upon the
Company's request, the Consultant shall return immediately to the Company all

<PAGE>

copies and other tangible manifestations of Confidential Information and all
Materials then in the Consultant's possession or control. The Consultant shall
return any Third Party Confidential Information upon request of the third party
or the Company.

7.    TERMINATION

      7.1 Early Termination for Failure to Close Equity Financing. In the event
that the Company fails to consummate an equity financing raising at least
$10,000,000 on or prior to October 31, 2001, the Company may in its discretion
terminate this Agreement upon no less than thirty (30) days' prior written
notice given to the Consultant no later than November 30, 2001.

      7.2 Early Termination by the Consultant. The Consultant may terminate this
Agreement at any time without cause upon written notice to the Company.

      7.3 Early Termination by Either Party for Breach. In the event of any
material breach of this Agreement by either party that is not cured within ten
(10) days after written notice from the non-breaching party, the non-breaching
party may terminate this Agreement by giving written notice to the breaching
party; provided that (a) if such breach is incapable of being cured, this
Agreement shall terminate immediately upon such notice and (b) if such breach is
capable of being cured but cannot be cured within such 10-day period and the
breaching party has promptly commenced action to cure such breach and is
diligently prosecuting such cure, such breach shall not constitute grounds for
termination unless it is not cured within ninety (90) days after the
non-breaching party's notice of such breach.

      7.4 Early Termination for Conflicting Research. In the event that
Consultant gives notice of his intent to perform research which is sponsored by
a third party commercial entity and in the Field pursuant to Section 1.4 above,
the Company may, at its option, terminate this Agreement upon not less than ten
(10) days' prior written notice to the Consultant given within thirty (30) days
after the Consultant's notice.

      7.5 Early Termination due to Death or Disability. This Agreement shall
terminate upon the death of the Consultant or upon 30 days' written notice from
either party in the event of the Consultant's Disability. As used herein,
"Disability" means the Consultant's inability by reason of physical or mental
impairment to perform the services contemplated herein for ninety (90) or more
days within any six-month period.

      7.6 Effect of Termination. Termination of this Agreement shall not affect
any liabilities accrued hereunder through the date of termination. The
provisions of Sections l.4(a), 5, 6, 7.6, and 8 shall survive termination;
provided that the Consultant's obligations under Sections 6.4 and 6.5 shall
survive for only five (5) years following termination. In the event this
Agreement is terminated after vesting and repurchase restrictions have been
imposed upon any shares of the Company's capital stock owned by the Consultant,
if and to the extent provided in a separate Restricted Stock Agreement between
Consultant and the Company, termination of this Agreement shall result in
termination of vesting of, and/or the imposition of repurchase rights with
respect to, certain shares held by the Consultant

<PAGE>

8.    MISCELLANEOUS

      8.1 Status. The Company and the Consultant agree that the Consultant will
be an independent contractor for all purposes, including but not limited to
payroll and tax purposes, and that the Consultant shall not, as a result of the
relationship established by this Agreement, in any way represent himself to be
an employee, partner, joint venturer or agent with or of the Company.

      8.2 Publicity. Subject to the policies of the Institution, Consultant
consents to the use by the Company of his name and likeness in written materials
or oral presentations to current or prospective customers, investors or others,
provided that such materials or presentations accurately and appropriately
describe the nature of Consultant's relationship with or contribution to the
Company, and further provided that Company shall have provided Consultant a
reasonable prior opportunity to review and comment thereon.

      8.3 Notice. All notices hereunder shall be in writing and shall be given
to the other party at the address or facsimile number set forth below, or at
such other address or facsimile number as either may specify in writing to the
other. All notices shall be effective when deposited in the United States mail
with proper postage for first class registered or certified mail, return receipt
requested, or when delivered personally or dispatched by facsimile, addressed:

If to the Company:                  CTI, Inc.
                                    1 Kendall Square
                                    Bldg 600
                                    Cambridge, MA 2139
                                    Facsimile:

If to the Consultant:               Mitchell P Fink
                                    109 Rockwood Drive
                                    Pittsburgh PA 15238
                                    Facsimile:  412-963-0550

      8.4 Assignment. This Agreement, and the rights and obligations hereunder,
may not be assigned or transferred by either party without the prior written
consent of the other party; provided that the Company may assign this Agreement
to any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business and/or assets of the
Company, but only if the Company obtains the agreement of such successor to
assume and agree to perform this Agreement in the same manner and to the same
extent that the Company would be required to perform it if no such succession
had taken place.

      8.5 Entire Agreement. This Agreement constitutes the entire agreement of
the parties, and supersedes all previous written or oral representations,
agreements and understandings between the Company and the Consultant, with
regard to the subject matter hereof. This Agreement may be amended or extended
only by a writing signed by both parties.(1)

<PAGE>

      8.6 Applicable Law. This Agreement shall be governed by, and construed in
accordance with, the law of The Commonwealth of Massachusetts without regard to
any choice of law principle that would dictate the application of the law of
another jurisdiction.

      8.7 Consent to Jurisdiction. The parties to this Agreement hereby
irrevocably consent and submit to the exclusive jurisdiction of any Commonwealth
of Massachusetts or Federal court sitting in Boston in any action or proceeding
of any type whatsoever arising out of or relating to this Agreement.

      The parties hereby cause this Agreement to be signed as an instrument
under seal.

                                         CRITICAL THERAPEUTICS, INC.

                                         By: /s/ H. Shaw Warren
                                             -----------------------------------
                                         Name:  H. Shaw Warren
                                         Title:  Chairman of Board CTI

                                         CONSULTANT:

                                         /s/ Michell Fink, M.D.
                                         ---------------------------------------
                                         Mitchell Fink, M.D.

<PAGE>

                                    EXHIBIT A

                                  CONFIDENTIAL

                    PREEXISTING RESTRICTIONS AND OBLIGATIONS:

      Consultant is party to a Consulting Agreement for Members of the Kairos
Critical Care Science, Inc. [now Galileo Laboratories] Scientific Advisory
Board.

      Consultant is party to a Consulting Agreement with CoAxia, Inc.

      Consultant is a party to a Consulting Agreement with Chiron Corporation.

<PAGE>
                           CRITICAL THERAPEUTICS, INC.

                                 AMENDMENT NO. 1

                                       TO

                              CONSULTING AGREEMENT

      This Amendment No.1 dated January 22, 2003 (the "Amendment") to the
Consulting Agreement dated January 31, 2001 (the "Agreement") between Critical
Therapeutics, Inc., a Delaware corporation (the "Company"), and Mitchell P.
Fink, M.D. (the "Consultant") is hereby entered into by the Company and the
Consultant. Except as set forth below, the Agreement shall remain in full force
and effect. Capitalized terms used herein and not otherwise defined shall have
the meanings assigned to them in the Agreement.

      For valuable consideration, receipt of which is acknowledged, the parties
hereto agree as follows:

      1. Acting in accordance with Section 8.5 of the Agreement, the Agreement
is hereby amended as follows:

            a. Section 2 shall be deleted in its entirety and a new Section 2
shall be inserted in lieu thereof which shall read as follows:

            "Subject to Section 7, this Agreement will be for a term beginning
as of January 31, 2001 and ending on January 31, 2007."

            b. Subsection 3.1 shall be deleted in its entirety and a new
Subsection 3.1 shall be inserted in lieu thereof which shall read as follows:

                  "Compensation. As full compensation for the Services, the
            Company shall pay the Consultant (i) $75,000 during the first year
            of this Agreement, (ii) $77,250 during the second year of this
            Agreement, (iii) $79,567.50 during the third year of this Agreement,
            (iv) $81,954.53 during the fourth year of this Agreement, (v)
            $84,413.17 during the fifth year of this Agreement and (vi)
            $86,945.57 during the sixth year of this Agreement. Such fees shall
            be payable bi-weekly in arrears in accordance with the Company's
            regular payroll practices."

      2. The Agreement, as supplemented and modified by this Amendment, together
with the other writings referred to in the Agreement or delivered pursuant
thereto which form a part thereof, contains the entire agreement among the
parties with respect to the subject matter thereof and amends, restates and
supersedes all prior and contemporaneous arrangements or understandings with
respect thereto.

      3. Upon the effectiveness of this Amendment, on and after the date hereof,
each reference in the Agreement to "this Agreement," "hereunder," "hereof,"
"herein" or words

<PAGE>

of like import, and each reference in the other documents entered into in
connection with the Agreement, shall mean and be a reference to the Agreement as
amended hereby. Except as specifically amended above, the Agreement shall remain
in full force and effect and is hereby ratified and confirmed.

      4. This Amendment shall be governed by, and construed in accordance with,
the law of The Commonwealth of Massachusetts without regard to any choice of law
principle that would dictate the application of the law of another jurisdiction.

      5. This Amendment may be executed in counterparts, and each such
counterpart shall be deemed to be an original instrument, but all such
counterparts together shall constitute but one agreement.

         [The remainder of this page has intentionally been left blank.]

<PAGE>

      IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1
to Consulting Agreement as of the day and year first above written.

                                         CRITICAL THERAPEUTICS, INC.

                                         By: /s/ Paul Rubin
                                             -----------------------------------
                                         Name:
                                         Title:

                                         CONSULTANT

                                         /s/ Mitchell Fink
                                         ---------------------------------------
                                         Mitchell P. Fink, M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]